Mineralys Therapeutics, Inc. (MLYS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Radnor, PA, United States. El CEO actual es Jon Congleton.
MLYS tiene fecha de IPO 2023-02-10, 51 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $1.81B.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
